Top Industry Leaders in the Vanishing Bone Disease Market
Latest Vanishing Bone Disease Companies Updates
AcelRX Therapeutics: Their Phase 2a clinical trial for their lead candidate, AC101, in VBD patients showed promising results with improvements in bone mineral density and reduced pain. This positive development paves the way for further clinical investigation and potentially faster market entry.
Volition Therapeutics: This biotech company secured $50 million in Series B funding to advance the development of their VTX201 for VBD treatment. This investment will fuel clinical trials and potentially accelerate their path to market.
BioMarin Pharmaceutical: Partnered with the University of California, San Diego, to develop and commercialize gene therapy treatments for VBD. This collaboration combines BioMarin's expertise in rare disease therapeutics with UCSD's cutting-edge gene therapy research.
Varian Medical Systems: Entered into a distribution agreement with a leading Chinese medical device company to bring their radiotherapy solutions for VBD to the Chinese market. This signifies the growing demand for VBD treatment options in emerging markets.
List of Vanishing Bone Disease Key companies in the market:
-
Varian Medical Systems, Inc
-
Elekta AB
-
C. R. Bard, Inc
-
Teleflex Incorporated
-
Vygon S.A
-
Medtronic plc
-
Cook Medical
-
Smiths Medical
-
ATMOS MedizinTechnik GmbH & Co. KG